Results 91 to 100 of about 757 (146)

Masthead: (View 2/2025)

VIEW, Volume 6, Issue 2, April 2025.
wiley   +1 more source

Efficacy and safety of azvudine in symptomatic adult COVID-19 participants who are at increased risk of progressing to critical illness: a study protocol for a multicentre randomized double-blind placebo-controlled phase III trial

Background Severe acute respiratory syndrome coronavirus 2 will coexist with humans for a long time, and it is therefore important to develop effective treatments for coronavirus disease 2019 (COVID-19).
Huaiya Xie, Yongjian Liu, Chongya Dong, Xinlun Tian, Xueqi Liu, Aohua Wu, Xiaoyan Yan, Mengzhao Wang, Siqi Pan, Luo Wang, Yaqi Wang, Jinglan Wang, Hong Zhang, Chen Yao, Junping Fan, Yan Xu   +15 more
core   +1 more source

Azvudine Suppresses Epithelial–Mesenchymal Transition in Hepatocellular Carcinoma by Targeting the Notch–HEY Signalling Pathway

Azvudine (FNC) is a novel cytidine analogue that is widely used in the treatment of infectious diseases such as AIDS and COVID-19. Previous studies have demonstrated its anticancer activity in various cancer cell lines, including non-Hodgkin’s lymphomas ...
Chunjie Xu, Zhonghui Zheng, Xuefu You, Yixin Ren, Xiujun Liu, Peiyi Sun, Xinyi Yang, Guoqing Li, Luyao Dong, Yao Meng, Hanhan Li   +10 more
core   +1 more source

Azvudine enhances durable tumor control with sotorasib in a CT26-mKRAS G12C syngeneic model

Introduction: KRAS G12C inhibitors can rapidly suppress oncogenic proliferative signaling and achieve meaningful initial tumor control, but their clinical benefit is often limited by on-treatment regrowth and restricted durability of response.
Zhiyong Qin, Limin Jia, Pan Li
core   +1 more source

Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19

Journal of Infection, 2023
Yuan Gao, Zujin Luo, Shan Ren, Zhonghui Duan, Ying Han, Huihang Liu, Ziwen Gao, Xinyu Zhang, Zhongjie Hu, Yingmin Ma   +9 more
openaire   +2 more sources

Efficacy of Azvudine Therapy in Patients with Severe and Non-Severe COVID‐19: A Propensity Score-Matched Analysis

Infection and Drug Resistance
Siqin Zhang,1,* Songsong Tan,1,* Bin Yang,2 Yaoyao Wu,3 Guohang Yuan,3 Fengjiao Chen,4 Lin Liu3,5 1Department of Endocrinology and Metabolism, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, 550002, People’s Republic of China; 2Department
Zhang S, Tan S, Yang B, Wu Y, Yuan G, Chen F, Liu L   +6 more
doaj  

In vitro comparison of the susceptibilities of the same drug resistance mutations to reverse-transcriptase inhibitors of subtype B and CRF01_AE HIV-1 strains

As the recommended drugs for first-line regimens in HIV-1 infections, reverse-transcriptase inhibitors (RTIs) are widely used around the world. To escape from the selective pressure imposed by RTIs, HIV-1 constantly mutates to adapt to its environment ...
Huimin Yan, Yongjian Liu, Jingwan Han, Lin Li, Kuiling Shen, Hanping Li, Lixuan Zhang, Bohan Zhang, Jingyun Li, Xiling Liu, Lei Jia, Erhei Dai, Xiaolin Wang   +12 more
core   +1 more source

Repurposing existing drugs for the treatment ofCOVID-19/SARS-CoV-2: A review of pharmacological effects and mechanism of action

Following the coronavirus disease-2019 outbreak caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an ongoing need to seek drugs that target COVID-19.
Peng Han, Shuchen Liu, Yunbo Sun, Yutong Liang, Xiaoxiao Quan, Zhuona Wu, Zhiyun Meng, Ruolan Gu, Guifang Dou, Hui Gan, Huajie Pan   +10 more
core   +1 more source

Azvudine for COVID-19 in Kidney Transplant Recipients: A Real-World Observational Study of Long-Term Renal Outcomes. [PDF]

J Clin Med
Li X, Xu X, Leng W, Deng S, Zhu Z, Zhang M, Han W, Zhang Y, Xiong G, Shen C, Lin J.   +10 more
europepmc   +1 more source

The first Chinese oral anti-COVID-19 drug Azvudine launched

The Innovation, 2022
Bin Yu, Junbiao Chang
openaire   +2 more sources